$SYBE Sybleu Inc. Purchases Fifty Percent Stake In
Post# of 35498
(Total Views: 92)
Posted On: 07/11/2023 8:23:51 AM
$SYBE Sybleu Inc. Purchases Fifty Percent Stake In Patent Protected Small Molecule Therapeutic Compounds, Anticipates Synergy With Recently In-Licensed AI/ML Engine
https://www.prnewswire.com/news-releases/sybl...72346.html
NEW YORK, July 11, 2023 /PRNewswire/ -- SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health.
On June 30, 2023 Sybleu entered into a purchase agreement whereby Sybleu purchased from Zander Biologics, Inc. a fifty percent ownership share of certain small molecule compounds with therapeutic applications. In return, Zander received a 10% Promissory Note in the principal amount of $300,000 due and payable June 30, 2025. Zander is also entitled to receive a contingent payment of 1,000,000 Sybleu common shares in the event documentation recording this transaction is filed with the US Patent and Trademark Office on or prior to July 31, 2023.
These compounds, currently patent protected in the U.S. under patent numbers US 10,472,351 B2 and US 11,377,442 B2, can potentially be developed into therapeutic agents targeting a host of companion animal ailments including cancer and arthritis. Sybleu intends to implement its strategy of synergizing its assets by applying its in-licensed AI/ML (Artificial Intelligence/Machine Learning) engine to further develop the purchased small molecule compounds.
"By using these patent protected compounds as part of the training dataset for our in-licensed AI/ML engine, we expect to create additional compounds that are specific for activation and inhibition of the NR2F6 receptor and which are already optimized for additional properties such as toxicity and solubility," said Harry Lander, Ph.D., CSO of Sybleu. "This will potentially save years of drug screening and chemical optimization work from the drug development pathway as well as those associated costs. We believe we will be able to quickly advance the science by marrying these technologies."
"We are extremely excited to begin the process of selectively identifying, acquiring and then developing first-rate intellectual property that fits within our corporate vision," said Joseph Vaini, CEO of Sybleu.
Sybleu and Zander have agreed to jointly develop and commercialize the jointly owned intellectual property for veterinary use with each party entitled to receive a 50% share of revenues and each party responsible for a 50% share of all expenses resulting from development and commercialization.
https://www.prnewswire.com/news-releases/sybl...72346.html
NEW YORK, July 11, 2023 /PRNewswire/ -- SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health.
On June 30, 2023 Sybleu entered into a purchase agreement whereby Sybleu purchased from Zander Biologics, Inc. a fifty percent ownership share of certain small molecule compounds with therapeutic applications. In return, Zander received a 10% Promissory Note in the principal amount of $300,000 due and payable June 30, 2025. Zander is also entitled to receive a contingent payment of 1,000,000 Sybleu common shares in the event documentation recording this transaction is filed with the US Patent and Trademark Office on or prior to July 31, 2023.
These compounds, currently patent protected in the U.S. under patent numbers US 10,472,351 B2 and US 11,377,442 B2, can potentially be developed into therapeutic agents targeting a host of companion animal ailments including cancer and arthritis. Sybleu intends to implement its strategy of synergizing its assets by applying its in-licensed AI/ML (Artificial Intelligence/Machine Learning) engine to further develop the purchased small molecule compounds.
"By using these patent protected compounds as part of the training dataset for our in-licensed AI/ML engine, we expect to create additional compounds that are specific for activation and inhibition of the NR2F6 receptor and which are already optimized for additional properties such as toxicity and solubility," said Harry Lander, Ph.D., CSO of Sybleu. "This will potentially save years of drug screening and chemical optimization work from the drug development pathway as well as those associated costs. We believe we will be able to quickly advance the science by marrying these technologies."
"We are extremely excited to begin the process of selectively identifying, acquiring and then developing first-rate intellectual property that fits within our corporate vision," said Joseph Vaini, CEO of Sybleu.
Sybleu and Zander have agreed to jointly develop and commercialize the jointly owned intellectual property for veterinary use with each party entitled to receive a 50% share of revenues and each party responsible for a 50% share of all expenses resulting from development and commercialization.
(0)
(0)Scroll down for more posts ▼